Medical Devices

31 tickers rated Hold in this theme
NewestHighest Score Ranks all matching reports in this category by score, highest first.
Boston Scientific Corporation
BSX·Healthcare
B ★★★Hold
Current$41.98
Target$51.20
Return+22.0%
Oct 31, 2026

Boston Scientific offers specialized medical-device franchises, strong cash generation, and recovery potential at a discounted valuation, but cardiovascular weakness, cybersecurity disruption, and Penumbra financing threaten near-term earnings growth.

Score
73
Knowles Corporation
KN·Technology
B ★★★Hold
Current$32.17
Target$35.70
Return+11.0%
Oct 26, 2026

Knowles benefits from rising demand for specialized defense, medical, and industrial electronic components, supported by strong orders and cash flow, but demanding valuation and manufacturing execution risks limit near-term upside.

Score
66
Thermo Fisher Scientific Inc.
TMO·Healthcare
B ★★★Hold
Current$673.82
Target$721.24
Return+7.0%
Oct 25, 2026

Thermo Fisher Scientific combines durable laboratory switching costs, recurring consumables, and recovering biopharma demand with strong cash generation, but demanding valuation and acquisition-related leverage limit near-term upside.

Score
73
Johnson & Johnson
JNJ·Healthcare
B ★★★Hold
Current$255.56
Target$257.62
Return+0.8%
Oct 19, 2026

Johnson & Johnson combines durable pharmaceutical franchises, strong cash generation, and a growing medical innovation portfolio, but elevated valuation, talc liabilities, and MedTech execution risks limit near-term upside.

Score
68
The Cooper Companies, Inc.
COO·Healthcare
B ★★★Hold
Current$54.14
Target$63.36
Return+17.0%
Sep 15, 2026

CooperCompanies offers a discounted entry into durable contact-lens and fertility franchises with strong cash flow and buybacks, but it must normalize U.S. channels and rebuild credibility after the Q3 guidance reset and failed CooperSurgical sale.

Score
70
Agilent Technologies, Inc.
A·Healthcare
B ★★★Hold
Current$157.93
Target$172.64
Return+9.3%
Aug 29, 2026

Agilent is a high-quality, cash-generative tollbooth in life sciences and analytical instruments with rapid margin expansion, though investors must accept a steep valuation premium amid cyclical biotech capex headwinds and China trade risk.

Score
84